• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Final Insights on Current Bladder Cancer Clinical Trials

Opinion
Video

Neal Shore, MD, FACS, shares his final thoughts on the current landscape of clinical trials for both non-muscle-invasive bladder cancer and muscle-invasive bladder cancer, providing insights into the potential impact and future directions of these studies.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following question(s):

      • Based on the data presented, how might these novel therapeutic approaches potentially change the standard of care and clinical management of NMIBC and MIBC in the future?
      Related Videos
      Advancing Hematologic Care and the Future of Shared Decision-Making
      Advancing Hematologic Care and the Future of Shared Decision-Making
      Advancing Multiple Myeloma Care: Insights From ASH 2024 and Beyond
      Advancing Multiple Myeloma Care: Insights From ASH 2024 and Beyond
      Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients
      Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients
      Anitocabtagene Autoleucel in Focus: Insights From the iMMagine-1 Trial at ASH 2024
      Anitocabtagene Autoleucel in Focus: Insights From the iMMagine-1 Trial at ASH 2024
      Main Conference Takeaways Regarding cGVHD Management
      Main Conference Takeaways Regarding cGVHD Management
      The Role of Posttransplant Cyclophosphamide in Patients With cGVHD
      The Role of Posttransplant Cyclophosphamide in Patients With cGVHD
      Discussing Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with cGVHD
      Discussing Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with cGVHD
      Exploring Combination Therapy with Ibrutinib and Rituximab in cGVHD
      Exploring Combination Therapy with Ibrutinib and Rituximab in cGVHD
      Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences
      Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences
      Transplant-Ineligible Myeloma and MRD Integration: Current Definitions and Future Directions
      Transplant-Ineligible Myeloma and MRD Integration: Current Definitions and Future Directions
      Related Content
      Highlights from AMCP Nexus 2024

      ICYMI: Highlights From AMCP Nexus 2024

      December 26th 2024
      Article

      Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.

      Read More

      Highlights From ASCO 2024

      ICYMI: Highlights From ASCO 2024

      December 21st 2024
      Article

      Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

      Read More

      Highlights from SLEEP 2024

      ICYMI: Highlights From SLEEP 2024

      December 18th 2024
      Article

      Check out our top 5 most-viewed pieces of coverage from the 2024 SLEEP meeting.

      Read More

      ICYMI: Highlights From ACTRIMS 2024

      ICYMI: Highlights From ACTRIMS 2024

      December 12th 2024
      Article

      Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS).

      Read More

      © 2025 MJH Life Sciences
      AJMC®
      All rights reserved.